공시 • May 23
BioStem Technologies, Inc. announced that it expects to receive $2.500001 million in funding BioStem Technologies Inc. announced that it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with its first institutional investor for the purchase and sale of 746,269 shares of common stock at a price of $3.35 per share for aggregate gross proceeds of approximately $2,500,001.15 on May 22, 2026. The closing of the offering is expected to occur on or about May 22, 2026, subject to the satisfaction of customary closing conditions. The offer and sale of the foregoing securities is being made in reliance on an exemption from the registration requirement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder, and applicable state securities laws, and the securities have not been and will not initially be registered under the Securities Act, or applicable state securities laws. 공시 • May 22
BioStem Technologies Announces Notice Of Allowance For Four U.S. Design Patent Applications Covering Fenestrated Human Placental Allografts And One European Patent BioStem Technologies®, a regenerative medicine company focused on developing and commercializing placental-derived biologics, announced that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for four new divisional U.S. design patent applications related to its fenestrated human placental allograft technologies. The European Patent Office also issued BioStem a new patent covering sterile human placental allografts and proprietary manufacturing methods for growth factor-rich placental tissue allografts. No. 30/010,024: FENESTRATED HUMAN PLACENTAL ALLOGRAFT The patent is directed to fenestrated human placental allograft designs intended to improve conformability, fluid transfer, and handling characteristics during clinical use. The technology supports applications in wound care and surgical environments where enhanced drainage, flexibility, and tissue integration may help optimize placement and healing outcomes. No. 30/010,026: FENESTRATED HUMAN PLACENTAL ALLOGRAFT The patent is directed to fenestrated human placental allograft designs that facilitate fluid management. The design supports use in wound care and surgical settings where effective drainage is important. No. 30/010,032: FENESTRATED HUMAN PLACENTAL ALLOGRAFT The patent is directed to fenestrated allograft designs that preserve the structural integrity of amniotic and chorion tissues while supporting moisture management in complex wound environments. No. 30/010,034: FENESTRATED HUMAN PLACENTAL ALLOGRAFT The patent is directed to fenestrated allograft designs that enable controlled fluid passage that supports wound drainage and overall wound management across a range of applications. Additionally, the European Patent Office issued BioStem a new patent covering sterile human placental allografts and proprietary methods of manufacturing growth factor-rich placental tissue allografts. EP4442316A2: STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOF The patent is directed to sterile human placental allografts and proprietary processing methods designed to preserve the natural structural integrity and endogenous growth factors of placental tissue. The technology utilizes gentle cleaning, low-temperature dehydration, and low-dose e-beam sterilization techniques to create growth factor-rich allografts for wound healing, dental, cosmetic and surgical applications, while supporting improved tissue regeneration and reduced immunogenic response. These patents represent continued momentum in BioStem's global intellectual property strategy, further strengthening a portfolio of more than 70 patents while advancing the development of next-generation products. BioStem’s proprietary processing technologies are designed to optimize preservation of the innate structural and biological characteristics of placental tissues, supporting their use in a variety of clinical applications, including wound care and surgical procedures. 공시 • May 16
BioStem Technologies, Inc. Provides Earnings Guidance for 2026 BioStem provided earnings guidance for 2026. The company expects its revenue for full year 2026 to be in the range of $25 million to $29 million. 공시 • May 02
BioStem Technologies, Inc. Appoints Katherine Gorrell as Chief Legal & Compliance Officer, Effective April 27, 2026 BioStem Technologies, Inc. announced the appointment of Katherine Gorrell as Chief Legal & Compliance Officer, effective April 27, 2026. Ms. Gorrell has an extensive career advising hospital systems and health technology companies, with deep experience in health law, regulatory, transactional, compliance, governance, and risk management, as well as other business-oriented legal functions that facilitate strategic expansion and ensure operational excellence. In her role, she will oversee BioStem’s legal and compliance functions and play a central role in enterprise governance, including the integration and oversight of Medical Affairs through BioStem’s compliance framework. Most recently Ms. Gorrell served as Vice President and General Counsel at Holy Cross Health in Fort Lauderdale, Florida, where she was as a member of the Executive Team and led legal strategy across a complex healthcare enterprise. She previously served as General Counsel and Compliance Officer for AdvancedMD, a national healthcare IT company, and held in-house roles at Intermountain Healthcare and Providence Health & Services/Swedish Health Services, advising across the full spectrum of operational, regulatory, and strategic matters. Ms. Gorrell holds a JD with Honors, with a concentration in Health Law, from the University of Washington School of Law, and a Bachelor of Arts with Honors in Political Science from the University of Utah. 공시 • May 01
BioStem Technologies, Inc. to Report Q1, 2026 Results on May 14, 2026 BioStem Technologies, Inc. announced that they will report Q1, 2026 results on May 14, 2026 공시 • Mar 26
BioStem Technologies, Inc. Provides Earnings Guidance for First Quarter of 2026 BioStem Technologies, Inc. provided earnings guidance for first quarter of 2026. For the period, the Company anticipates first quarter revenue to be in the range of $5 million to $6 million. 
